四川科伦博泰生物医药股份有限公司（06990.HK）近日宣布，其自主研发的候选药物SKB565已获得中国国家药品监督管理局（NMPA）的临床试验申请（IND）批准。该药物旨在用于治疗晚期实体瘤。这一里程碑标志着公司在肿瘤治疗领域的研发管线迈出了关键一步。
四川科伦博泰生物医药股份有限公司（06990.HK）近日宣布，其自主研发的候选药物SKB565已获得中国国家药品监督管理局（NMPA）的临床试验申请（IND）批准。该药物旨在用于治疗晚期实体瘤。这一里程碑标志着公司在肿瘤治疗领域的研发管线迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.